Does weight-loss surgery reduce inflammatory markers in saliva and gum inflammation in adults with obesity and gum disease?

Short-term changes in salivary IL-6, TNF-a, and periodontal inflammation following sleeve gastrectomy in patients with obesity: a randomized controlled pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN70883045

Enrollment

Registered

2026-07-27

Start date

2022-12-01

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and stage I-III periodontitis Oral Health

Interventions

After eligibility confirmation, baseline periodontal examination and baseline saliva collection, participants were assigned to one of two parallel groups by simple computer-generated randomization wit

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years 2. Body mass index (BMI) >=35 kg/m² with obesity-related comorbidities, or BMI >=40 kg/m² 3. Stage I-III periodontitis according to the 2018 periodontitis stage/grade classification 4. At least 12 natural teeth per arch to permit reliable periodontal examination

Exclusion criteria

Exclusion criteria: 1. Smoking more than 10 cigarettes per day 2. Periodontal treatment within the previous 6 months 3. Pregnancy or lactation 4. Previous bariatric surgery 5. Systemic diseases known to markedly affect periodontal inflammation, including active autoimmune disorders or malignant disease 6. Recent antibiotic use 7. Recent systemic corticosteroid use 8. Regular non-steroidal anti-inflammatory drug use within 90 days 9. Current anti-obesity glucagon-like peptide-1 (GLP-1) therapy

Design outcomes

Primary

Measure	Time frame
Salivary interleukin-6 concentration measured using Concentration in pg/mL measured in unstimulated whole saliva using a commercially available enzyme-linked immunosorbent assay (ELISA). Samples were assayed in duplicate and the mean result was used at baseline, 3 months and 6 months; the principal comparison was change from baseline to 6 months;Salivary tumour necrosis factor-alpha concentration measured using Concentration in pg/mL measured in unstimulated whole saliva using a commercially available enzyme-linked immunosorbent assay (ELISA). Samples were assayed in duplicate and the mean result was used at baseline, 3 months and 6 months; the principal comparison was change from baseline to 6 months	—

Measure

Time frame

Salivary interleukin-6 concentration measured using Concentration in pg/mL measured in unstimulated whole saliva using a commercially available enzyme-linked immunosorbent assay (ELISA). Samples were assayed in duplicate and the mean result was used at baseline, 3 months and 6 months; the principal comparison was change from baseline to 6 months;Salivary tumour necrosis factor-alpha concentration measured using Concentration in pg/mL measured in unstimulated whole saliva using a commercially available enzyme-linked immunosorbent assay (ELISA). Samples were assayed in duplicate and the mean result was used at baseline, 3 months and 6 months; the principal comparison was change from baseline to 6 months

—

Countries

Romania

Contacts

Public ContactGabriela Beresescu

felicia.beresescu@umfst.ro+40 745134184

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 25, 2026